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A B S T R A C T
Background: Sample size in research projects is estimated before initiation of
the study to minimise type 1 and type 2 error, while keeping the study's ﬁnancial cost and subject enrolment to a minimum. This study investigates project-speciﬁc
factors potentially associated with correct estimation of sample size in study protocols.
Methods: Examination of 189 non-commercially sponsored study protocols (84 randomised controlled trials (RCTs) and 105 non-RCT studies) submitted to the
Scientiﬁc Ethics Committees of The Capitol Region of Denmark from 2013 to 2015.
Results: 119 (63%) study protocols contained a sample size calculation, with a signiﬁcantly higher rate of sample size calculations in RCT vs non-RCT study protocols
(76% vs. 52%, p < 0.001). Signiﬁcantly more intervention studies than non-intervention studies (69% vs 52%, p=0.020), studies including blood samples
compared to those without (69% vs. 55%, p=0.045), studies funded by a foundation donation compared to those with no funding (68% vs. 49%, p=0.040)
performed sample size calculations. Further, increasing number of sick patients enrolled (p=0.048) and newer studies (p=0.032) were more likely to include a
sample size calculation in the protocol.
Conclusions: Estimation of sample size is more often reported in RCT than non-RCT study protocols. Also, intervention studies, studies funded by a foundation
donation, studies including blood samples, studies with a greater amount of sick participants and chronologically newer study protocols more often reported a sample
size calculation.
1. Introduction
Estimation of projected sample size of a medical research study is
based on the hypothesis proposed by the investigators. For various
reasons investigators sometimes fail to determine sample size before
initiation of the study and consequently base their projected number of
participants on experience, logistics or something even more un-
scientiﬁc [1]. A sample size too small increases the risk of type 2 error,
whereas a study with too many participants potentially exposes re-
search subjects to unnecessary risk and uses up excess resources [2].
Previous studies have explored underpowered designs and how the
concept of statistical power can be misused and is often misunderstood
[2–4]. Recent studies have investigated sample size estimation em-
pirically [1,5,6]. Notably, in regards to randomised controlled trials
(RCTs) conducted in the UK one study from 2013 reported that only
42% of the protocols supplied all the information needed to repeat the
sample size calculation. Non-commercially sponsored studies were less
likely to report all the information and researchers tended to over-
estimate their sample size [1]. A French study from 2009 found that
among selected MEDLINE RCT-articles, 43% did not present enough
information to repeat the sample size calculation, while 5% did not
report conducting a sample size calculation at all [5].An American
study from 2015 showed that only 56% of clinical trials of analgesics
reported a sample size calculation, but just 38% included all the
parameters needed to recalculate the sample size. The authors also
found that RCTs reported a sample size calculation more often than
other experimental study types [6].
To extend previous knowledge, the aim of this study was to in-
vestigate sample size estimation practices and use of statistical sample
size calculation in non-commercially sponsored original research pro-
tocols submitted to the Scientiﬁc Ethics Committees of The Capitol
Region of Denmark. Speciﬁcally, we identiﬁed project-speciﬁc in-
dicators possibly associated with correct or incorrect statistical sample
size calculation and sample size estimation.
2. Methods
2.1. Identiﬁcation of research protocols
In Denmark, all original research protocols are submitted to one of
ﬁve central Scientiﬁc Ethics Committees corresponding to the ﬁve
geographical regions in the country. One of these regions is the Capitol
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Region (greater Copenhagen), which receive approximately 700 ori-
ginal research protocols annually (an annual mean of 721 through
2013–2017). This number is roughly equal to the total number of re-
search protocols evaluated by the other four Regional Scientiﬁc Ethics
Committees combined.
We identiﬁed non-commercially sponsored study protocols sub-
mitted from January 2013 onwards and included, consecutively, all
protocols until July 2015 when 89 RCT protocols were ascertained.
Only non-commercial study protocols were included to ensure that
sample size calculation was not performed or included in the study
design by a commercial sponsor before the academic investigators were
involved in the study design. Commercially sponsored studies usually
include a power calculation as per company tradition, and therefore
may not reﬂect the individual academic investigators' practices. During
this period 100 random non-RCT protocols were included for compar-
ison. Inclusion of the earliest versions of the protocols was prioritized to
more reliably represent the original research intention of the in-
vestigators. As per Danish law research protocols must include some
considerations about participant number but not necessarily a mathe-
matical sample size calculation. This sampling strategy was based on
the assumption that, in order to detect at least a 20% diﬀerence in the
prevalence of reported sample size estimation in two groups (our pri-
mary study endpoint); RCT protocols= 75% and non-RCT proto-
cols= 55%, 86 protocols were needed in each category with a power of
80% (β=0.2) at the 95% signiﬁcance level (α=0.05) in the two
groups.
2.2. Data extraction
For each study protocol data were extracted from the protocol re-
port formula, the statistical subsection of the protocol, and the study
participant information, which were the documents covered by the
right of access. As per Danish law it is possible for all citizens (option
pursued particularly by journalists and other researchers who perform
meta-research) to apply for right of access to individual research project
documents. The documents concerning this project were delivered to
the authors by the administrative personnel of the Scientiﬁc Ethics
Committees of The Capitol Region of Denmark via secure delivery of
PDF (portable document ﬁles). The extracted data were organised in a
database comprising the following exposure variables: study type
(RCT/non-RCT), researcher's academic status (junior/senior), re-
searcher's gender (female/male), institution (state hospital/regional
hospital and non-hospital), intervention (treatment/other intervention/
none), biobank status (existing biobank/new biobank/none), study
participant remuneration (yes/no), multistate study (yes/no), ﬁeld of
medicine (internal medicine/surgery/other), procedures involved
(electromagnetic radiation exposure/blood sample/biopsy/none), eco-
nomic funding (state funded/medicinal company funded/foundation
donation funded/no funding), study length (months), participants
(number of healthy/sick), study sessions (number), time to new year
(weeks), time passed since 2013 (months).
Although study type was stated by the researcher in the protocol
report formula, not always did it match the actual study type and
subsequently the authors re-classiﬁed the study type by evaluating the
participant information form and the study description found in the
protocol report formula. Of the 89 protocols submitted as RCTs, only 84
were determined to be RCTs when the protocol report formulae and the
study participant information were examined by the authors.
2.3. Evaluation of sample size estimation
Information on the following components of sample size estimation
was extracted from the statistical subsection of the protocols: α (sig-
niﬁcance level), β (power), expected proportion of drop-outs, eﬀect size
(minimal relevant diﬀerence, MIREDIF) and standard deviation (or two
proportions, if the study compared proportions). Further, an estimation
of sample size was performed by the authors based on the reported
components and compared to the reported sample size in the protocol.
Whether a sample size calculation was performed by the researcher
in the study protocol was our primary outcome. As supporting sec-
ondary analysis, we constructed a sample size calculation component
composite score (SSCCCS) ranging from 0 to 6 with one point given for
enough information conveyed to reproduce correctly the calculation
and achieving the same sample size estimate, and one point for each of
the following ﬁve constants reported; α, β, expected dropout fraction,
eﬀect size and standard deviation (or two proportions).
The data analysis was conducted in SPSS version 25, using logistic
and linear regression functions.
3. Results
In total 189 study protocols were identiﬁed and analysed; 84 (44%)
were RCTs, 23 (12%) were other type of experimental studies, 37 (20%)
were analytical studies, 32 (17%) were descriptive studies, and 13 (7%)
were studies including secondary data analysis (e.g. stored tissue
samples) (Fig. 1).
The researcher's academic status and gender were senior in 138
(73%) studies and male in 112 (59%) studies. 77 (41%) studies were
Fig. 1. Classiﬁcation of the included studies.
The ﬂowchart describes the authors' algorithm used to divide the studies in the
ﬁve categories.
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conducted by the state hospital, while the rest were conducted in re-
gional hospitals and non-hospital institutions. 93 (49%) studies in-
volved treatment, whereas 14 (7%) involved some other interventions.
84 (44%) of the studies were in the ﬁeld of internal medicine and 24
(13%) were in surgery. 107 (57%) of the studies included blood samples
as procedure, 37 (20%) involved electromagnetic radiation exposure
(such as X-ray), and 20 (11%) included biopsies. 134 (71%) of the
studies were funded by a foundation donation, while, respectively, 8
(4%) and 14 (7%) studies were state funded and medicinal company
funded; 33 (18%) had no funding (Table 1).
Of the 84 RCTs, 64 (76%) performed a sample size calculation, 62
(74%) reported eﬀect size, 54 (64%) reported standard deviation, 63
(75%) reported α, 66 (79%) reported β, 42 (50%) reported expected
dropout fraction, and 45 (54%) contained a sample size calculation
reproducible by the authors. Of the 105 non-RCTs 55 (52%) performed
a sample size calculation, 51 (49%) reported eﬀect size, 43 (41%) re-
ported standard deviation, 55 (52%) reported α, 58 (55%) reported β,
32 (30%) reported expected dropout fraction, and 31 (30%) contained a
calculation reproducible by the authors. The primary endpoint, a
comparison between sample size calculations performed in RCT vs.
non-RTC study protocols, showed that signiﬁcantly more RCTs per-
formed a sample size calculation (76% vs 52%, p < 0.001). The mean
SSCCCS was 4.0 (SD 2.3) for RCT study protocols and 2.6 (SD 2.4) for
non-RCT protocols, p < 0.001 (Fig. 2).
The two most common explanations for not including a sample size
calculation in the protocols where sample size calculation was not
performed were; missing data (38%), e.g. SD not accessible, and sample
size calculation done prior or later (24%), reported in the protocol as
some kind of sample size estimation calculation was to be done later or
was done prior to the protocol but with no mention of the calculation
itself, whereas the rationale for the proposed sample size was often not
explained (35%) or based on the investigators research experience
(32%) (Table 2).
The following extracted variables were statistically signiﬁcantly
associated with having performed a correct sample size calculation in
the protocol (Table 3): RCT vs. non-RCTs (OR 2.91, 95% CI 1.55–5.47,
p=0.001), studies with treatment and other intervention vs. studies
with no intervention (OR 2.03, 95% CI 1.12–3.69, p= 0.020), studies
from the state hospital vs. regional and non-hospital institutions (OR
1.88, 95% CI 1.01–3.49, p= 0.046), studies with foundation donation
funding vs. no funding (OR 2.25, 95% CI 1.04–4.87, p=0.040), studies
including blood samples vs. studies without blood samples (OR 1.84,
95% CI 1.01–3.35, p= 0.045), increasing number of sick participants
(OR 1.09 per 25 sick participant sample increase, 95% CI 1.00–1.20,
p=0.048) and increasing time passed since 1st of January 2013 (OR
1.04 per month increase, 95% CI 1.00–1.07, P= 0.032).
In linear regression analysis of the SSCCCS RCTs vs. non-RCTs (score
increase by 1.38, 95% CI of 0.70–2.06, p < 0.001), studies with female
vs. male investigators (score increase by 0.739, 95% CI 0.03–1.45,
p=0.041), studies with treatment and other intervention vs. none
Table 1
Characteristics of the included study protocols.
RCT N=84 Non-RCT N=105 Total N=189
Researcher's academic status, N (%) Junior 24 (28.6) 27 (25.7) 51 (27.0)
Senior 60 (71.4) 78 (74.3) 138 (73.0)
Researcher's gender, N (%) Female 35 (41.7) 42 (40.0) 77 (40.7)
Male 49 (58.3) 63 (60.0) 112 (59.3)
Institution, N (%) State hospital 31 (36.9) 46 (43.8) 77 (40.7)
Regional hospital 53 (63.1) 59 (56.2) 112 (59.3)
Non-hospital 2 (2.4) 1 (1.0) 3 (1.6)
Intervention, N (%) Treatment 77 (91.7) 14 (13.3) 93 (49.2)
Other intervention 7 (8.3) 43 (41.0) 14 (7.4)
None 0 (0.0) 48 (45.7) 82 (43.4)
Biobank, N (%) Existing biobank 0 (0.0) 15 (14.3) 15 (7.9)
New biobank 43 (51.2) 49 (46.7) 92 (48.7)
None 41 (48.8) 44 (39.0) 85 (45.0)
Remuneration, N (%) Yes 27 (32.1) 29 (27.6) 56 (29.6)
Multistate project, N (%) Yes 9 (10.7) 10 (9.5) 19 (10.1)
Field of medicine, N (%) Internal medicine 41 (48.8) 43 (41.0) 84 (44.4)
Surgery 10 (11.9) 14 (13.3) 24 (12.7)
Other 33 (33.9) 48 (45.7) 81 (42.9)
Invasive procedures, N (%) Electromagnetic radiation exposure 17 (20.2) 20 (19.0) 37 (19.6)
Blood sample 51 (60.7) 56 (53.3) 107 (56.6)
Biopsy 8 (9.5) 12 (11.4) 20 (10.6)
None 27 (32.1) 41 (39.0) 68 (36.0)
Economical funding, N (%) State funded 3 (3.6) 5 (4.8) 8 (4.2)
Medicinal company funded 7 (8.3) 7 (6.7) 14 (7.4)
Foundation donation funded 62 (73.8) 72 (68.6) 134 (70.9)
No funding 12 (14.3) 21 (20.0) 33 (17.5)
Study length, mean (SD) Months 26 (33) 39 (119) 33 (90)
Participants, median (range) Total 42 (1492) 70 (5435) 50 (5435)
Health 0 (450) 10 (3400) 0 (3400)
Sick 30 (1500) 40 (5441) 40 (5441)
Sessions, mean (SD) Sessions 4.1 (2.8) 2.6 (3.4) 3.2 (3.3)
Time to new year, mean (SD) Weeks 19 (9) 14 (9) 16 (10)
Time passed since 2013, mean (SD) Months 13 (7) 12 (7) 13 (7)
SSCCCS, mean (SD) Points 4.0 (2.3) 2.6 (2.4) 3.2 (2.5)
Non-RCT: Include experimental, analytical, descriptive and secondary data analysis study types.
Electromagnetic radiation exposure: Include all procedures with x-rays or radioactive isotopes.
Biopsy procedures: Include skin, muscle, liver, fatty tissue, and bone marrow biopsies.
Funding: The main funder of the study.
Time to new year: Measured as the shorter of the two following; number of days that has passed from submit of protocol to new year or number of days from
submission of protocol to new year.
Time passed since 2013: Number of months passed from the ﬁrst of January 2013 to submission of protocol.
SSCCCS: Sample size calculation component composite score.
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(score increase by 0.78, 95% CI 0.08–1.48, p= 0.030), and studies
funded by foundations vs. studies with no funding (score increase by
1.39, 95% CI 0.47–2.31, p=0.003) were associated with a higher score
of SSCCCS.
4. Discussion
RCT protocols submitted to the Scientiﬁc Ethics Committees of The
Capitol Region of Denmark were more inclined to include a sample size
calculation compared to other study designs. This may be explained by
the consensus that research trials including treatments or interventions
should be conducted more carefully since the subjects potentially are at
a greater risk compared to other study types. An increasing number of
projected sick participants in the study also increased the likelihood of
including a sample size calculation in the protocol, possibly also ex-
plained by the greater respect when the study involves treatment.
Studies funded by a foundation included a sample size calculation
more often than studies funded by other means and studies not funded.
More strict foundation regulations possibly explain this. Also, in-
vestigators pursuing funding with major funding bodies likely pay more
attention to important details of their study's design, and consequently
studies including realistic and scientiﬁcally sound considerations about
projected sample size are more likely to obtain funding.
Interestingly, more sample size calculations were performed in
newer studies (from 2013 through 2015). This could be explained by
more awareness in general among researchers about power and sample
size in scientiﬁc studies as time passes.
Our study has several strengths: the consecutive inclusion of study
protocols during a speciﬁed time period led to a random pattern of
study characteristics in our sample thus reducing bias. The wide variety
of project-speciﬁc explanatory variables included increased the in-
formation extracted from this study. The centralised structure of the
Danish scientiﬁc ethics committees ensured a complete coverage of
protocols since no local institutional review boards exist. The single,
homogenous protocol report formula proved to be an easy way to
standardize data, which if multiple formulae types were involved could
induce confusion and misunderstanding. Conversely, it is a limitation of
the study that it only included a small sample of protocols in a limited
geographical area.
Ideally, planning of all studies with quantitative analysis involving
human subjects should include a sample size estimation [7]. However,
some study designs make sample size calculations diﬃcult, speciﬁcally
Fig. 2. Reported components of sample size calculation.
Frequencies of reported components of sample size calculation. The numbers in the columns represent the total number, whereas the Y-axis indicates the percentage.
The ﬁrst, darker column in the pairs represents the RCT, whereas the lighter second in the pairs represents the non-RCTs.
Table 2
Characteristics of study protocols with missing sample size calculation.
RCT Descriptive Experimental Analytical Secondary data analysis Total
N=16 N=18 N=13 N=20 N=5 N=72
Researcher's reason for not including a sample size calculation in the protocol
Explorative study, N (%) 12 (60.0) 7 (38.9) 6 (46.2) 6 (37.5) 2 (40.0) 33 (45.8)
Incalculable design, N (%) 3 (15.0) 4 (22.2) 2 (15.4) 3 (18.8) 0 (0.0) 12 (16.7)
Calculated prior or later, N (%) 1 (5.0) 3 (16.7) 4 (30.8) 6 (37.5) 3 (60.0) 17 (23.6)
None, N (%) 4 (20.0) 4 (22.2) 1 (7.7) 1 (6.3) 0 (0.0) 10 (13.9)
Researcher's sample size rationale
Similar studies, N (%) 5 (25.0) 0 (0.0) 1 (7.7) 3 (18.8) 0 (0.0) 9 (12.5)
Experience, N (%) 1 (5.0) 9 (50.0) 5 (38.5) 5 (31.3) 3 (60.0) 23 (31.9)
Predetermined size, N (%) 1 (5.0) 1 (5.6) 2 (15.4) 2 (12.5) 1 (20.0) 7 (9.7)
Calculated prior or later, N (%) 3 (15.0) 3 (16.7) 1 (7.7) 1 (6.3) 0 (0.0) 8 (11.1)
None, N (%) 10 (50.0) 5 (27.8) 4 (30.8) 5 (31.3) 1 (20.0) 25 (34.7)
When sample size was estimated without a calculation, the reason for missing calculation (values: missing data/pilot study/incalculable design/calculated prior or
later/none) and the sample size rationale (values: similar studies/experience/predetermined size/calculated prior or later/none) were found in the statistical sub-
section of the protocol.
Explorative study: some constant or variable (e.g. SD) is unknown, often not speciﬁed which in the protocol.
Incalculable design: the sample size calculation deemed ”incalculable” by the investigator due to the study design.
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pilot studies within a ﬁeld so unexplored that no constants can be used
in the calculation [8]. The interpretation of studies with inadequate or
missing sample size calculations could potentially diﬀer greatly from
studies with correct calculation of sample size. Studies with too few
research subjects risk failing to reject the null hypothesis, but also risk
accepting a false hypothesis that otherwise would have been rejected if
additional research subjects had been enrolled. In contrast, studies with
an abundancy of research subjects unethically waste funds and subject
additional participants to unnecessary hazard without a clear justiﬁ-
cation.
Our investigation conﬁrmed that estimation of sample size is more
often performed in RCTs than non-RCT studies. We extend previous
ﬁndings by showing that several project-speciﬁc factors increase the
probability of reporting a sample size calculation in scientiﬁc protocols.
Particularly, intervention studies, studies funded by a foundation do-
nation, studies conducted at the state hospital, studies with blood
samples drawn, studies with a high number of sick participants and
chronologically newer studies are more likely to report a sample size
calculation. This study increases the knowledge within a sparsely stu-
died area and highlight the importance of adequate sample size esti-
mation in academic research projects. The knowledge generated by this
study is important for researchers from academia as well as members of
scientiﬁc ethics committees and institutional review boards when
evaluating the impact and soundness of research. Further, it ultimately
may prevent the initiation of unjustiﬁed and unsound research that
exposes patients to unnecessary harm and possibly delays important
knowledge from being adopted by the research community and in
clinical practice.
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Factors associated with having performed a sample size calculation in the included study protocols.
Factor Calculation performed OR (95% CI) P-value
Study type, N (%) RCT 64 (76.2) 2.91 (1.55–5.47) 0.001
Non-RCT 55 (52.4) 1.00
Researcher's academic status, N (%) Junior 34 (66.7) 1.25 (0.63–2.45) 0.552
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Researcher's gender, N (%) Female 54 (70.1) 1.70 (0.92–3.14) 0.091
Male 65 (58.0) 1.00
Institution, N (%) State hospital 64 (53.8) 1.88 (1.01–3.49) 0.046
Others 55 (46.2) 1.00
Intervention, N (%) Yes 74 (69.2) 2.03 (1.12–3.69) 0.020
No 43 (52.4) 1.00
Biobank
Existing, N (%) Yes 15 (60.0) 0.87 (0.30–2.57) 0.804
No 110 (63.2) 1.00
New, N (%) Yes 63 (68.5) 1.59 (0.88–2.89) 0.126
No 56 (57.7) 1.00
Remuneration, N (%) Yes 85 (63.9) 0.87 (0.46–1.66) 0.678
No 109 (64.1) 1.00
Multistate, N (%) Yes 10 (52.6) 0.62 (0.24–1.61) 0.325
No 34 (60.7) 1.00
Field of medicine, N (%) Internal medicine 54 (64.3) 1.11 (0.59–2.10) 0.734
Surgery 15 (62.5) 1.03 (0.40–2,65) 0.945
Others 50 (61.7) 1.00
Procedures involved
Electro-magnetic radiation exposure, N (%) Yes 23 (62.2) 0.96 (0.46–2.01) 0.958
No 96 (63.2) 1.00
Blood sample, N (%) Yes 74 (69.2) 1.84 (1.01–3.35) 0.045
No 45 (54.9) 1.00
Biopsy, N (%) Yes 12 (60.0) 0.87 (0.34–2.24) 0.772
No 107 (67.5) 1.00
None, N (%) Yes 79 (67.5) 0.60 (0.33–1.10) 0.099
No 40 (55.6) 1.00
Economic funding, N (%) State funded 5 (62.5) 1.77 (0.36–8.65) 0.480
Medicinal company funded 7 (50.0) 1.06 (0.30–3.71) 0.924
Foundation donation funded 91 (67.9) 2.25 (1.04–4.87) 0.040
None 16 (48.5) 1.00
Study Length (OR per month) 0.01 (0.99–1.02) 0.358
Participants, healthy (OR per 25) 1.01 (0.98–1.05) 0.492
Participants, sick (OR per 25) 1.09 (1.00–1.20) 0.048
Sessions (OR per 1) 0.96 (0.88–1.05) 0.350
Time till/from new year (OR per weeks) 0.99 (0.96–1.04) 0.904
Time passed since 2013 (OR per month) 1.04 (1.00–1.07) 0.032
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